Home
Intersect ENT, Inc.

Intersect ENT, Inc. Market Share Analysis for April 2026

People-centered, data-driven, personalized. Solving our world’s biggest health challenges with advanced technology.

Health > Health - Other

Domainintersectent.com

Year Founded2003

Employees201 - 500

Annual Revenue$100M - $200M

Intersect ENT, Inc.

Intersect ENT, Inc. (including company regionals)

intersectent.com

See more website traffic and engagement information

Intersect ENT, Inc. Revenue up to April 2026 is 100M - 200M

revenue generated by Intersect ENT, Inc. top domains

Intersect ENT, Inc. top domains revenue over 3 years

Revenue for Intersect ENT, Inc. top domains

intersectent.com100M - 200M

See more with Sales Intelligence

Total visits to Intersect ENT, Inc.'s top domains

Understand Intersect ENT, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Intersect ENT, Inc.'s top domains

Analyze Intersect ENT, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Intersect ENT, Inc.'s top domains

See how Intersect ENT, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Intersect ENT, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Intersect ENT, Inc.

These are the website technologies, by industry, used by Intersect ENT, Inc. top domains

Advertising (8)

DoubleClick

Email Services (3)

Sendgrid

Marketing (3)

Google Marketing Platform

Widget (3)

Twemoji

More Technologies

10

See all

News & Signals from Intersect ENT, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsIntersect ENT, Inc. launches SINUVA.Intersect ENT Inc., a subordinate company of Medtronic, introduced SINUVA, a non-surgical option used to treat nasal polyposis, eliminating all symptoms within a period of 90 days.

NewsIntersect ENT, Inc. acquired Fiagon for $71.1M on Jan 1st '20.In 2020, Intersect ENT, a USA-based ear, nose, and throat condition treatment developer, announced to acquire Fiagon for USD 71.1 million.

NewsIntersect ENT, Inc. launched VenSure balloon sinus dilation system on Jul 1st '21.• In July 2021, Intersect ENT has launched its VenSure balloon sinus dilation system and Cube 4D navigation systems.